GSK plc announced plans to establish a new flagship R&D centre on the Cambridge Biomedical Campus in the UK, investing £400 million over three years. The 300,000 square foot facility will house more than 1,000 scientists and support research in Oncology, Respiratory, Hepatology, Vaccines, and HIV. The move involves vacating the Stevenage site by 2029 and upgrading laboratories in Ware to integrate drug development and commercial manufacturing. This investment aims to accelerate the R&D pipeline by leveraging the local biomedical ecosystem. GSK is a global biopharma company focused on vaccines, specialty medicines, and consumer healthcare.

GSK plc’s licensor, Hansoh Pharma, announced positive results from the ARTEMIS-011 phase III trial for risvutatug rezetecan (Ris-Rez) in China. The study met its primary endpoint of progression-free survival in patients with relapsed osteosarcoma, demonstrating statistically significant and clinically meaningful improvements compared with chemotherapy. Consistent benefits were observed in overall survival, with no new safety signals identified. These data will support a regulatory submission in China. GSK holds exclusive global rights to develop Ris-Rez outside mainland China, Hong Kong, Macau, and Taiwan, and is advancing the asset in global trials for sarcomas, lung cancer, and prostate cancer. Ris-Rez has received US FDA Breakthrough Therapy Designation for relapsed or refractory osteosarcoma. GSK plc is a global biopharmaceutical company focused on vaccines, specialty medicines, and consumer healthcare.

GSK plc announced that the European Medicines Agency has accepted a submission to update the Bexsero label to include a single-dose booster for individuals aged 10 years and older. The submission is supported by Phase 3b study data showing the booster dose is effective in boosting immune responses in individuals previously vaccinated during infancy. GSK is a global biopharma company that develops and distributes vaccines and medicines to fight disease.

GSK plc announced the conclusion of a competitive tender process led by the Audit & Risk Committee. The Board decided to re-appoint Deloitte LLP as the company's external auditor starting from the financial year ending 31 December 2028. Shareholders will vote on this re-appointment at the 2028 Annual General Meeting. GSK is required to tender the statutory audit every 10 years. The company is a global biopharma company that develops medicines and vaccines.

GSK plc has announced that it will not progress further development of camlipixant in refractory chronic cough (RCC) following mixed results from phase III clinical trials CALM-1 and CALM-2. While CALM-1 met its primary endpoint with 50mg twice daily, CALM-2 failed to reach statistical significance for the same dose at week 24, and the 25mg dose showed no significance in either study. GSK will continue to evaluate camlipixant in adults with irritable bowel syndrome (IBS-D and IBS-M) via the phase IIb BALANCE trial. GSK is a global biopharma company focused on disease prevention and treatment.